LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 753

Search options

  1. Book ; Online ; E-Book: The new Hepatitis C

    Reau, Nancy / Jensen, Donald M.

    effective clinical management in the age of all-oral therapy

    (Oxford American infectious disease library)

    2018  

    Author's details edited by Nancy Reau, Donald M. Jensen
    Series title Oxford American infectious disease library
    Keywords Hepatitis C ; Hepatitis C / drug therapy ; Antiviral Agents / therapeutic use
    Language English
    Size 1 Online-Ressource (xii, 187 Seiten), Illustrationen
    Edition Second edition
    Publisher Oxford University Press
    Publishing place New York
    Publishing country United States
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019637295
    ISBN 978-0-19-023829-2 ; 9780190238285 ; 0-19-023829-1 ; 0190238283
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book: Controversies in hepatology

    Jensen, Donald M.

    the experts analyze both sides

    2011  

    Abstract: ... of an academic debate. Dr. Donald Jensen is joined by 50 colleagues who present evidence-based arguments for and ...

    Author's details Donald M. Jensen
    Abstract "The field of hepatology is full of controversies and clinical dilemmas. Each day, gastroenterologists and hepatologists are faced with the challenge of making the best evidence-based decision in challenging cases that do not readily lend themselves to an easy answer, even with today's available medical literature. Controversies in Hepatology: The Experts Analyze Both Sides is based on the principle of an academic debate. Dr. Donald Jensen is joined by 50 colleagues who present evidence-based arguments for and against 17 key controversial areas in hepatology. Each point-counterpoint is then followed up by a summarization of key points by a leading expert in that topic area. Some Chapter Topics Include: Should living donor liver transplantation be considered in adult acute liver failure? Should hepatitis C be treated in patients with chronic kidney disease prior to kidney transplant? Resect or observe asymptomatic hepatic adenoma? Strictly adhere to the "6-month rule" for recent history of alcohol abuse in potential liver transplant candidates? Autoimmune hepatitis: maintenance therapy for all patients or stop treatment after histologic remission? With concise clinical information to reinforce the point-counterpoint text, Controversies in Hepatology: The Experts Analyze Both Sides will become the go-to resource for teaching and perfecting the important skills required to weigh the evidence and arrive at an outcome"--Provided by publisher
    Keywords Liver Diseases / therapy ; Liver Diseases / diagnosis ; Decision Making ; Evidence-Based Medicine
    Language English
    Size XV, 177 S.
    Publisher SLACK
    Publishing place Thorofare, NJ
    Publishing country United States
    Document type Book
    Note Includes bibliographical references and index
    HBZ-ID HT017076439
    ISBN 978-1-55642-950-7 ; 1-55642-950-9
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Book: Advances in cholestatic liver disease

    Jensen, Donald M.

    (Clinics in liver disease ; 12,1)

    2008  

    Author's details guest ed. Donald M. Jensen
    Series title Clinics in liver disease ; 12,1
    Collection
    Language English
    Size XIV, 242 S. : Ill.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT015511764
    ISBN 1-4160-5838-9 ; 978-1-4160-5838-0
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Book: Cholestasis

    Jensen, Donald M.

    (Clinics in liver disease ; 8,1)

    2004  

    Author's details guest ed. Donald M. Jensen
    Series title Clinics in liver disease ; 8,1
    Collection
    Language English
    Size XII, 254 S. : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT014005323
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  5. Article ; Online: The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.

    Jensen, Donald M / Rzepczynski, Allison / Jensen, Emily E / Reau, Nancy

    Hepatology (Baltimore, Md.)

    2022  Volume 76, Issue 3, Page(s) 854–859

    MeSH term(s) History, 20th Century ; Humans ; Liver Diseases/therapy ; Societies, Medical ; United States/epidemiology
    Language English
    Publishing date 2022-04-30
    Publishing country United States
    Document type Historical Article ; Journal Article
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1002/hep.32521
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book: Cholestasis

    Jensen, Donald M.

    (Clinics in liver disease ; 3,3)

    1999  

    Author's details Donald M. Jensen, guest ed
    Series title Clinics in liver disease ; 3,3
    Collection
    Language English
    Size XIV S., S. 433 - 692 : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT010916832
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  7. Article ; Online: Opportunities and challenges in commercial pharmaceutical liposome applications.

    Jensen, Gerard M / Hodgson, Donald F

    Advanced drug delivery reviews

    2020  Volume 154-155, Page(s) 2–12

    Abstract: In the 1980s, the center of entrepreneurial activity for the application of liposome science to medicine took the form of a company called Vestar Inc. (which became NeXstar Pharmaceuticals Inc., and eventually a division of Gilead Sciences, with merger ... ...

    Abstract In the 1980s, the center of entrepreneurial activity for the application of liposome science to medicine took the form of a company called Vestar Inc. (which became NeXstar Pharmaceuticals Inc., and eventually a division of Gilead Sciences, with merger and acquisition activity). This company was formed from science initially developed at the California Institute of Technology and the City of Hope, and involving several other local academic and treatment centers. This company eventually produced two commercial liposomal therapeutics, and created a particular paradigm of formulation goals, formulation development, characterization, and production unique among the set of companies that emerged around the same time. A number of clinical candidates were also developed, but failed to achieve commercialization. Nevertheless, several of these provide still relevant lessons and guidance for the field. Key adaptations of this technology to lower cost applications have also been carried out and are examined.
    MeSH term(s) Animals ; Anti-Bacterial Agents/administration & dosage ; Antineoplastic Agents/administration & dosage ; Communicable Diseases/drug therapy ; Humans ; Liposomes ; Neoplasms/drug therapy
    Chemical Substances Anti-Bacterial Agents ; Antineoplastic Agents ; Liposomes
    Language English
    Publishing date 2020-07-22
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 639113-8
    ISSN 1872-8294 ; 0169-409X
    ISSN (online) 1872-8294
    ISSN 0169-409X
    DOI 10.1016/j.addr.2020.07.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Advances in combination regimens in the management of HCV infection.

    Jensen, Donald M

    Gastroenterology & hepatology

    2014  Volume 10, Issue 2, Page(s) 134–136

    Language English
    Publishing date 2014-02-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.

    Cotter, Thomas G / Jensen, Donald M

    Drug design, development and therapy

    2019  Volume 13, Page(s) 2565–2577

    Abstract: Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV ... ...

    Abstract Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.
    MeSH term(s) Aminoisobutyric Acids ; Antiviral Agents/chemical synthesis ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Benzimidazoles/chemical synthesis ; Benzimidazoles/chemistry ; Benzimidazoles/pharmacology ; Cyclopropanes ; Drug Design ; Hepacivirus/drug effects ; Hepatitis C, Chronic/drug therapy ; Humans ; Lactams, Macrocyclic ; Leucine/analogs & derivatives ; Microbial Sensitivity Tests ; Molecular Conformation ; Proline/analogs & derivatives ; Pyrrolidines ; Quinoxalines/chemical synthesis ; Quinoxalines/chemistry ; Quinoxalines/pharmacology ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry ; Sulfonamides/pharmacology
    Chemical Substances Aminoisobutyric Acids ; Antiviral Agents ; Benzimidazoles ; Cyclopropanes ; Lactams, Macrocyclic ; Pyrrolidines ; Quinoxalines ; Sulfonamides ; pibrentasvir (2WU922TK3L) ; Proline (9DLQ4CIU6V) ; Leucine (GMW67QNF9C) ; glecaprevir (K6BUU8J72P)
    Language English
    Publishing date 2019-07-29
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S172512
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Patterns of failure after radiosurgery for WHO grade 1 or imaging defined meningiomas: Long-term outcomes and implications for management.

    Rock, Calvin B / Weil, Christopher R / Rock, Christian B / Gravbrot, Nicholas / Burt, Lindsay M / DeCesaris, Cristina / Menacho, Sarah T / Jensen, Randy L / Shrieve, Dennis C / Cannon, Donald M

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

    2024  Volume 120, Page(s) 175–180

    Abstract: Background: We analyzed long-term control and patterns of failure in patients with World Health Organization Grade 1 meningiomas treated with definitive or postoperative stereotactic radiosurgery at the authors' affiliated institution.: Methods: 96 ... ...

    Abstract Background: We analyzed long-term control and patterns of failure in patients with World Health Organization Grade 1 meningiomas treated with definitive or postoperative stereotactic radiosurgery at the authors' affiliated institution.
    Methods: 96 patients were treated between 2004 and 2019 with definitive (n = 57) or postoperative (n = 39) stereotactic radiosurgery. Of the postoperative patients, 17 were treated adjuvantly following subtotal resection and 22 were treated as salvage at time of progression. Patients were treated to the gross tumor alone without margin or coverage of the dural tail to a median dose of 15 Gy. Median follow up was 7.4 years (inter-quartile range 4.8-11.3). Local control, marginal control, regional control, and progression-free survival were analyzed.
    Results: Local control at 5 and 10 years was 97 % and 95 %. PFS at 5 and 10 years was 94 % and 90 % with no failures reported after 6 years. Definitive and postoperative local control were similar at 5 (95 % [82-99 %] vs. 100 %) and 10 years (92 % [82-99 %] vs. 100 %). Patients treated with postoperative SRS did not have an increased marginal failure rate (p = 0.83) and only 2/39 (5 %) experienced recurrence elsewhere in the cavity.
    Conclusions: Stereotactic radiosurgery targeting the gross tumor alone provides excellent local control and progression free survival in patients treated definitively and postoperatively. As in the definitive setting, patients treated postoperatively can be treated to gross tumor alone without need for additional margin or dural tail coverage.
    MeSH term(s) Humans ; Meningioma/diagnostic imaging ; Meningioma/radiotherapy ; Meningioma/surgery ; Radiosurgery/methods ; Treatment Outcome ; Progression-Free Survival ; Retrospective Studies ; Meningeal Neoplasms/diagnostic imaging ; Meningeal Neoplasms/radiotherapy ; Meningeal Neoplasms/surgery ; Follow-Up Studies
    Language English
    Publishing date 2024-01-22
    Publishing country Scotland
    Document type Journal Article
    ZDB-ID 1193674-5
    ISSN 1532-2653 ; 0967-5868
    ISSN (online) 1532-2653
    ISSN 0967-5868
    DOI 10.1016/j.jocn.2024.01.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top